CytomX Therapeutics Inc (CTMX) concluded trading on Thursday at a closing price of $2.6, with 3.72 million shares of worth about $9.68 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 128.07% during that period and on July 10, 2025 the price saw a gain of about 4.42%. Currently the company’s common shares owned by public are about 157.54M shares, out of which, 103.99M shares are available for trading.
Stock saw a price change of 4.84% in past 5 days and over the past one month there was a price change of -1.33%. Year-to-date (YTD), CTMX shares are showing a performance of 100.00% which increased to 152.43% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.40 but also hit the highest price of $3.10 during that period. The average intraday trading volume for CytomX Therapeutics Inc shares is 5.21 million. The stock is currently trading 7.50% above its 20-day simple moving average (SMA20), while that difference is up 23.10% for SMA50 and it goes to 115.96% higher than SMA200.
CytomX Therapeutics Inc (NASDAQ: CTMX) currently have 157.54M outstanding shares and institutions hold larger chunk of about 35.39% of that.
The stock has a current market capitalization of $409.62M and its 3Y-monthly beta is at 2.14. PE ratio of stock for trailing 12 months is 5.24, while it has posted earnings per share of $0.50 in the same period. It has Quick Ratio of 1.73 while making debt-to-equity ratio of 0.33. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CTMX, volatility over the week remained 6.98% while standing at 9.39% over the month.
Stock’s fiscal year EPS is expected to drop by -124.50% while it is estimated to decrease by -337.98% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on May 15, 2025 offering a Buy rating for the stock and assigned a target price of $5 to it. Coverage by Piper Sandler stated CytomX Therapeutics Inc (CTMX) stock as an Overweight in their note to investors on April 14, 2025, suggesting a price target of $2.50 for the stock. On May 28, 2024, Piper Sandler Upgrade their recommendations, while on May 09, 2024, Wedbush Upgrade their ratings for the stock with a price target of $8. Stock get a Buy rating from Jefferies on May 06, 2024.
